⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14659147 | 1.00 | — | — | |
| SCHEMBL7154734 | 1.00 | — | — | |
| SCHEMBL16431979 | 1.00 | — | — | |
| SCHEMBL30685402 | 1.00 | — | — | |
| SCHEMBL27657848 | 1.00 | — | — | |
| SCHEMBL7639836 | 0.86 | — | — | |
| SCHEMBL9789754 | 0.81 | — | — | |
| SCHEMBL7644341 | 0.78 | — | — | |
| SCHEMBL7640249 | 0.78 | — | — | |
| SCHEMBL16431290 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | claimed |
| EP-3328439-A1 | MULTILIGAND AGENT FOR DRUG DELIVERY | Arcturus Therapeutics, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| WO-2017023817-A1 | MULTILIGAND AGENT FOR DRUG DELIVERY | ARCTURUS THERAPEUTICS, INC. (US) | 2017-02-09 | — | — | WO | claimed |
| US-7538092-B2 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2009-05-26 | — | — | US | claimed |
| EP-1549350-B1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DE GMBH (DE) | 2008-09-24 | — | — | EP | claimed |
| US-20060100163-A1 | Pharmaceutically active oligosaccharide conjugates | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2006-05-11 | — | — | US | claimed |
| US-20050267169-A1 | Watersoluble prodrugs of propofol | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2005-12-01 | — | — | US | claimed |
| EP-1554242-A1 | WATERSOLUBLE PRODRUGS OF PROPOFOL | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-20 | — | — | EP | claimed |
| EP-1549350-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | Fresenius Kabi Deutschland GmbH (DE) | 2005-07-06 | — | — | EP | claimed |
| WO-2004032971-A1 | PHARMACEUTICALLY ACTIVE OLIGOSACCHARIDE CONJUGATES | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| WO-2004033424-A1 | WATERSOLUBLE PRODRUGS OF PROPOFOL | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2004-04-22 | — | — | WO | claimed |
| US-12569570-B2 | Compositions and methods for targeted RNA delivery | VERVE THERAPEUTICS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260053912-A1 | STEROLS AS NOVEL IMMUNOMODULATORY AGENTS AND THEIR USE AS VACCINE ADJUVANTS | UNITED STATES GOVERNMENT | 2026-02-26 | — | — | US | disclosed |
| EP-4700124-A2 | OLIGONUCLEOTIDE-LIGAND CONJUGATES AND PROCESS FOR THEIR PREPARATION | Alnylam Pharmaceuticals, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12478671-B2 | Sterols as novel immunomodulatory agents and their use as vaccine adjuvants | OHIO STATE INNOVATION FOUNDATION (US) | 2025-11-25 | — | — | US | disclosed |
| EP-1301191-A1 | POTENT IMMUNOSTIMULANTS FROM MICROALGAE | The University of Mississippi (US) | 2003-04-16 | — | — | EP | disclosed |
| US-20030055012-A1 | Prodrugs of COX-2 inhibitors | PHARMACIA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| WO-2002083655-A1 | PRODRUGS OF COX-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2002-10-24 | — | — | WO | disclosed |
| WO-2002068436-A1 | AVILAMYCIN DERIVATIVES | COMBINATURE BIOPHARM AG (DE) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002004000-A1 | POTENT IMMUNOSTIMULANTS FROM MICROALGAE | THE UNIVERSITY OF MISSISSIPPI (US) | 2002-01-17 | — | — | WO | disclosed |